An agent that is both an SSRI–selective serotonin reuptake inhibitor and a partial 5-HT1A receptor agonist which is FDA-approved for managing major depressive disorder.
Contraindications Concomitant treatment with MAOIs-monoamine oxidase inhibitors, given the risk of serotonin syndrome.
Adverse effects Diarrhoea, nausea, insomnia, vomiting
Proprietary name Viibryd™
Reference Product literature, Forest Pharmaceuticals